Ll-37 — reference
A human cathelicidin antimicrobial peptide with roles in innate immunity and wound healing.
Regulatory status
Not FDA-Approved. Not approved for therapeutic use. Naturally produced in the body; administering it exogenously is not a studied intervention.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of Short — rapidly proteolyzed in vivo; not well characterized in humans. Most data comes from in-vitro antimicrobial/immune studies, not systemic PK.
This figure is tagged Not characterised in our evidence system. No reliable human pharmacokinetic data was found for this compound. We publish that fact rather than a number borrowed from an unreliable source. Any estimated curve here would be fiction, and should be treated as such. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Ll-37 FDA-approved?
What is the half-life of Ll-37?
How reliable is that half-life figure?
What cautions are associated with Ll-37?
Does Peptide Plug publish dosing for Ll-37?
Does Peptide Plug sell Ll-37?
Related tools
Free, no account required.